Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - - Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with

Related Keywords

Florida ,United States ,Orlando ,American ,Dennis Riedl ,Theriva Biologics ,Stevena Shallcross ,Mark Schroeder ,Chris Calabrese ,Lifesci Advisors ,Washington University School Of Medicine ,Company Annual Report On Form ,Theriva Biologics Inc ,Washington University ,Safety Monitoring Committee ,Orlando World Center Marriott ,Division Of Oncology ,Cellular Therapy Meetings ,Chief Executive Officer ,Hematopoietic Cell Transplant ,Associate Professor ,Bone Marrow Transplantation ,Washington University School ,Germ Cell ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Theriva ,Iologics ,Nnounces ,Presentation ,Safety ,Pharmacokinetic ,Data ,Rom ,Cohort ,Hase ,Linical ,Trial ,Ibaxamase ,Allogeneic ,Ematopoietic ,Fell ,Transplant ,Recipients ,